Arvind Arora

Arvind Arora

University of Nottingham - Nottingham / United Kingdom
Medical and Health Sciences / General Surgery
AD Scientific Index ID: 1257259
person_outline Arvind Arora's MOST POPULAR ARTICLES
1-) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trialA Lamarca, DH Palmer, HS Wasan, PJ Ross, YT Ma, A Arora, S Falk, ...The Lancet Oncology 22 (5), 690-701, 20212772021
2-) ABC-06| A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+ mFOLFOX) for patients (pts …A Lamarca, DH Palmer, HS Wasan, PJ Ross, YT Ma, A Arora, S Falk, ...Journal of Clinical Oncology 37 (15_suppl), 4003-4003, 20192542019
3-) Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancerTMA Abdel-Fatah, FK Middleton, A Arora, D Agarwal, T Chen, ...Molecular oncology 9 (3), 569-585, 2015952015
4-) The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarraysN Tewari, AM Zaitoun, A Arora, S Madhusudan, M Ilyas, DN LoboBMC cancer 13, 1-10, 2013942013
5-) Human helicase RECQL4 drives cisplatin resistance in gastric cancer by activating an AKT–YB1–MDR1 signaling pathwayD Mo, H Fang, K Niu, J Liu, M Wu, S Li, T Zhu, MA Aleskandarany, A Arora, ...Cancer Research 76 (10), 3057-3066, 2016932016